The Irvine, Calif.-based company posted a net loss of -$32.4 million, or -89¢ per share, for the 3 months ended Sept. 30, for bottom-line loss of -36% compared with the same period last year.
Adjusted to exclude 1-time items, earnings per share were -71¢, behind consensus on The Street.
“The third quarter, and certainly the last few weeks, have proven to be quite successful for Aerie by any measure,” chairman & CEO Vicente Anido, Jr., said in prepared remarks. “We are delighted with the recent positive FDA advisory committee vote, the excellent progress we are making in preparing to launch Rhopressa in the United States, the commencement of our international clinical trial activities, as well as the enhancement of our preclinical pipeline focused on retinal disease. We very much look forward to driving all of our initiatives forward as we continue to build Aerie.”
AERI shares were trading at $63.30 apiece today in morning activity, down -0.8%.